Vera Therapeutics Investor Relations Material

Vera Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing and commercializing treatments aimed at serious immunological diseases. Their portfolio includes atacicept, a fusion protein undergoing clinical trials for immunoglobulin A nephropathy and Phase II trials for lupus nephritis. Another significant development in their pipeline is MAU868, a monoclonal antibody targeting the BK virus in transplant patients. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.